Abstract
Purpose
To evaluate the effectiveness of corticosteroid‐sparing immunosuppressive therapy (IMT) in patients with recurrent or sight‐threatening central multifocal choroiditis (MFC).
Methods
Retrospectively, data were collected prior to and after the start of treatment with IMT at 3, 6, 12 and 24 months of follow‐up (FU) and at the end of FU. Outcome measures were best‐corrected visual acuity (BCVA), percentage of patients achieving disease control and/or a corticosteroid‐free stadium of disease after the start of the IMT, the number of recurrences/year of inflammation and/or neovascularisations before and after the start of IMT and the number of anti‐vascular endothelial growth (VEGF) injections/year before and after the start of IMT. The minimum FU period was 12 months after the start of IMT.
Results
31 patients (38 eyes) were included in a single‐center. At 12 months after the start of IMT, mean BCVA was Snellen 0.74. A corticosteroid‐free stadium of disease was achieved by 35.5% and disease control by 54.8% of the patients at 12 months. Seventeen patients (20 eyes) had a FU period of at least 12 months prior to the start of IMT. The mean number of recurrences/year in this group significantly decreased from 1.85 (±1.37) to 0.61 (±0.66) (p = 0.001) after the start of IMT. The number of anti‐VEGF injections decreased from 2.87 (±3.40) to 1.75 (±2.76) (p = 0.071).
Conclusions
IMT is effective in patients with MFC with recurrent or sight‐threatening disease by reducing the number of relapses.
To evaluate the effectiveness of corticosteroid‐sparing immunosuppressive therapy (IMT) in patients with recurrent or sight‐threatening central multifocal choroiditis (MFC).
Methods
Retrospectively, data were collected prior to and after the start of treatment with IMT at 3, 6, 12 and 24 months of follow‐up (FU) and at the end of FU. Outcome measures were best‐corrected visual acuity (BCVA), percentage of patients achieving disease control and/or a corticosteroid‐free stadium of disease after the start of the IMT, the number of recurrences/year of inflammation and/or neovascularisations before and after the start of IMT and the number of anti‐vascular endothelial growth (VEGF) injections/year before and after the start of IMT. The minimum FU period was 12 months after the start of IMT.
Results
31 patients (38 eyes) were included in a single‐center. At 12 months after the start of IMT, mean BCVA was Snellen 0.74. A corticosteroid‐free stadium of disease was achieved by 35.5% and disease control by 54.8% of the patients at 12 months. Seventeen patients (20 eyes) had a FU period of at least 12 months prior to the start of IMT. The mean number of recurrences/year in this group significantly decreased from 1.85 (±1.37) to 0.61 (±0.66) (p = 0.001) after the start of IMT. The number of anti‐VEGF injections decreased from 2.87 (±3.40) to 1.75 (±2.76) (p = 0.071).
Conclusions
IMT is effective in patients with MFC with recurrent or sight‐threatening disease by reducing the number of relapses.
| Original language | English |
|---|---|
| Pages (from-to) | 16-16 |
| Journal | Acta Ophthalmologica |
| Volume | 97 |
| Issue number | S262 |
| Publication status | Published - Mar 2019 |